CALT vs. MLYS, GHRS, ZYME, PHAT, ANAB, PHVS, LYEL, AVBP, PHAR, and ABUS
Should you be buying Calliditas Therapeutics AB (publ) stock or one of its competitors? The main competitors of Calliditas Therapeutics AB (publ) include Mineralys Therapeutics (MLYS), GH Research (GHRS), Zymeworks (ZYME), Phathom Pharmaceuticals (PHAT), AnaptysBio (ANAB), Pharvaris (PHVS), Lyell Immunopharma (LYEL), ArriVent BioPharma (AVBP), Pharming Group (PHAR), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical preparations" industry.
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, community ranking, analyst recommendations and valuation.
Mineralys Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -40.19%. Mineralys Therapeutics' return on equity of -32.48% beat Calliditas Therapeutics AB (publ)'s return on equity.
In the previous week, Calliditas Therapeutics AB (publ) had 32 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 34 mentions for Calliditas Therapeutics AB (publ) and 2 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.89 beat Calliditas Therapeutics AB (publ)'s score of 0.01 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.
Calliditas Therapeutics AB (publ) presently has a consensus target price of $34.00, suggesting a potential downside of 10.41%. Mineralys Therapeutics has a consensus target price of $33.50, suggesting a potential upside of 175.49%. Given Mineralys Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Mineralys Therapeutics is more favorable than Calliditas Therapeutics AB (publ).
Calliditas Therapeutics AB (publ) received 17 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 57.45% of users gave Calliditas Therapeutics AB (publ) an outperform vote.
Calliditas Therapeutics AB (publ) has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of 2.05, meaning that its stock price is 105% more volatile than the S&P 500.
2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Comparatively, 33.2% of Mineralys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Calliditas Therapeutics AB (publ) has higher revenue and earnings than Mineralys Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Mineralys Therapeutics beats Calliditas Therapeutics AB (publ) on 11 of the 17 factors compared between the two stocks.
Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically
Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Calliditas Therapeutics AB (publ) Competitors List
Related Companies and Tools
